Clinical-phase |
INO-4800 |
DNA plasmid encoding S protein delivered via
electroporation |
Inovio Pharmaceuticals |
Phase I
(NCT04336410) |
|
mRNA-1273 |
LNP-encapsulated mRNA vaccine encoding S protein |
Moderna |
Phase I (NCT04283461) |
|
LV-SMENP-DC |
DCs modified with lentiviral vector expressing synthetic
minigene based upon domains of selected viral proteins; |
Shenzhen
Geno-Immune Medical Institute |
Phase I (NCT04276896) |
|
/ |
Recombinant novel coronavirus (2019-CoV) vaccine (adenoviral
vector) |
Institute of Military Medicine under the Academy of Military
Sciences of the People’s Liberation Army of China |
Phase II
(ChiCTR2000030906) |
|
/
|
Inactivated vaccine
|
Beijing Institute of Biological Products/Wuhan Institute of Biological
Products
|
Phase I
(ChiCTR2000031809)
|
|
ChAdOx1
|
Attenuated adenovirus capable of producing the S protein of
SARS-CoV-2
|
University of Oxford
|
Phase I/II
(NCT04324606)
|
|
Ad5-nCoV |
Adenovirus type 5 vector that expresses S protein |
CanSino
Biologicals |
Phase I (NCT04313127) |
|
Pathogen-specific aAPC |
aAPCs modified with lentiviral vector
expressing synthetic minigene based upon domains of selected viral
proteins |
Shenzhen Geno-Immune Medical Institute |
Phase I
(NCT04299724) |
Experimental-phase |
/ |
Single-dose intranasal replication-defective
adenovirus vector vaccine incorporating the SARS-CoV-2 S protein |
Altimmune |
Phase 1 trial planned for mid-August. |
|
BNT162 |
mRNA vaccine expressing codon-optimized undisclosed
SARS-CoV-2 proteins |
BioNTech |
Clinical testing to begin late
April |
|
STARR |
Self-transcribing and replicating RNA vaccine expressing
undisclosed epitopes |
Arcturus |
Manufacturing stage |
|
/ |
Protamine-complexed mRNA-based vaccine expressing undisclosed
SARS-CoV-2 protein(s) |
CureVac |
Phase 1 planned in June or
July |
|
/ |
Undisclosed SARS-CoV-2-derived synthetic peptide conjugated to the
key moiety of the MHC II–associated invariant chain |
Generex
Biotechnology |
Human trials planned in June |
|
/ |
Modified vaccinia Ankara VLP vaccine based upon Wuhan strain of
SARS-CoV-2 |
GeoVax |
Candidates in animal studies |
|
/ |
Electroporated linear DNA vaccine based on S protein and selected
epitopes |
LineaRx |
Four candidates for testing by the beginning of May
or June |
|
/ |
Undisclosed recombinant SARS-CoV-2 protein VLP produced in tobacco |
Medicago |
preclinical testing ongoing with clinical trials to begin
summer 2020 |
|
/ |
Recombinant subunit vaccine of SARS-CoV-2 S protein locked in
prefusion conformation by polypeptide moiety (molecular clamp) |
University of Queensland |
Preclinical as of mid-March |
|
/ |
Oral recombinant adenovirus 5 vector vaccine of undisclosed
SARS-CoV-2 proteins for mucosal immune response |
Vaxart |
Preclinical
as of mid-March |